2024-05-08 13:23 | CC:RKV | Rakovina Therapeutics Inc | 0.09 | News Release200 | Rakovina expands Deep Docking research partnerships |
2024-04-26 22:16 | CC:RKV | Rakovina Therapeutics Inc | 0.09 | SEDAR MD & A815 | SEDAR MD & A |
2024-04-26 21:51 | CC:RKV | Rakovina Therapeutics Inc | 0.09 | SEDAR Audited Annual Financial Statements804 | SEDAR Audited Annual Financial Statements |
2024-04-26 20:47 | CC:RKV | Rakovina Therapeutics Inc | 0.09 | News Release200 | Rakovina Therapeutics ends 2023 with cash of $436,313 |
2024-04-19 19:33 | CC:RKV | Rakovina Therapeutics Inc | 0.09 | Shares for Debt330 | Rakovina Therapeutics 255,425 shares for debt |
2024-04-09 16:18 | CC:RKV | Rakovina Therapeutics Inc | 0.09 | News Release200 | Rakovina presents data on kt-3000 series at AACR |
2024-04-01 10:16 | CC:RKV | Rakovina Therapeutics Inc | 0.10 | News Release200 | Rakovina hires Insight Capital for advisory services |
2024-03-27 16:23 | CC:RKV | Rakovina Therapeutics Inc | 0.095 | News Release200 | Rakovina signs agreement for Deep Docking AI platform |
2023-11-27 19:54 | CC:RKV | Rakovina Therapeutics Inc | 0.07 | News Release200 | Rakovina has cash of $813,328 at Sept. 30 |
2023-11-27 19:07 | CC:RKV | Rakovina Therapeutics Inc | 0.07 | SEDAR Interim MD & A813 | SEDAR Interim MD & A |
2023-11-27 19:04 | CC:RKV | Rakovina Therapeutics Inc | 0.07 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
2023-11-27 12:59 | CC:RKV | Rakovina Therapeutics Inc | 0.07 | News Release200 | Rakovina appoints Cherkasov as scientific adviser |
2023-11-20 14:25 | CC:RKV | Rakovina Therapeutics Inc | 0.075 | News Release200 | Rakovina appoints Hamerlik as scientific adviser |
2023-08-29 17:44 | CC:RKV | Rakovina Therapeutics Inc | | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
2023-08-29 17:38 | CC:RKV | Rakovina Therapeutics Inc | | SEDAR Interim MD & A813 | SEDAR Interim MD & A |
2023-08-29 13:45 | CC:RKV | Rakovina Therapeutics Inc | 0.105 | News Release200 | Rakovina spends $391,969 on R&D in Q2 2023 |
2023-06-29 00:01 | CC:RKV | Rakovina Therapeutics Inc | 0.135 | News Release200 | Rakovina shareholders re-elect four directors at AGM |
2023-06-14 18:33 | CC:RKV | Rakovina Therapeutics Inc | 0.135 | Private Placement - Debenture255 | Rakovina $1,514,000 debenture private placement |
2023-05-31 14:03 | CC:RKV | Rakovina Therapeutics Inc | 0.13 | News Release200 | Rakovina spends $433,344 on R&D in Q1 2023 |
2023-05-30 21:36 | CC:RKV | Rakovina Therapeutics Inc | 0.13 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
2023-05-30 21:36 | CC:RKV | Rakovina Therapeutics Inc | 0.13 | SEDAR MD & A815 | SEDAR MD & A |
2023-05-29 21:03 | CC:RKV | Rakovina Therapeutics Inc | 0.13 | News Release200 | Rakovina closes $1.5-million debenture financing |